FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics
Kino T, Hatanaka H, Hashimoto M et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiotics 1987 40 : 1249.
FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro
Kino T, Hatanaka H, Miyata S et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II: Immunosuppressive effect of FK-506 in vitro. J Antibiotics 1987 40 : 1256 1265. (Pubitemid 17138110)
Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic®) in canine atopic dermatitis: A randomized, double-blinded, placebo-controlled, cross-over study
Marsella R, Nicklin CF, Saglio S, Lopez J. Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic®) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. Vet Dermatol 2004 15 : 294 303.
In vitro measurement of canine and feline IgE: A review of FceR1a-based assays for detection of allergen-reactive IgE
Grieve RB, Wassom DL. In vitro measurement of canine and feline IgE: a review of FceR1a-based assays for detection of allergen-reactive IgE. Vet Dermatol 1998 9 : 173 178.
Tacrolimus (marketed as Protopic Ointment) Information. . Accessed July
Tacrolimus (marketed as Protopic Ointment) Information. US Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm107845.htm. Accessed July 2009.